Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy With and Without Spontaneous Lobar Hemorrhage.
Benedetta Storti, Giulia Marinoni, Benedetta Cefaloni...
https://pubmed.ncbi.nlm.nih.gov/40932118/Actively Recruiting
Led by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Updated on 2026-03-30
500
Participants Needed
1
Research Sites
182 weeks
Total Duration
Researchers are investigating cerebral amyloid angiopathy CAA, a major type of small vessel disease in the brain that can cause spontaneous brain bleeding and cognitive decline in older adults. This study aims to better understand the diseases natural history, clinical signs, brain imaging features, and progression by collecting detailed patient data. The SENECA project is Italys first multicenter cohort study focused on improving diagnosis and knowledge of CAA through a multidisciplinary approach. The study collects demographic, clinical, and neuroradiological data from patients diagnosed with possible, probable, or definite CAA, including both symptomatic and asymptomatic cases. Participants must have had at least one brain MRI. Neurologists gather information on patient history, symptoms, vascular risks, family history, and treatments. This observational study involves a network of specialists working together to standardize data collection and build a large biorepository of CAA patients. Participants will undergo clinical and neuroradiological evaluations over 24 months to monitor disease characteristics and severity. Data collection includes brain imaging and clinical records to identify markers of disease progression. The study monitors patients without administering treatments, focusing on understanding CAAs course to inform future clinical guidelines. The total observation period for each participant is at least two years, with ongoing assessments during this time.
CONDITIONS
SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)
A
Anna Bersano, MD, Phd
R
Renato Mantegazza, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 24 months
Participants diagnosed with cerebral amyloid angiopathy undergo collection of demographic, clinical, and neuroradiological data by neurologists.
Data collection visits as scheduled by neurologists
Duration - Up to 24 months
Participants are observed over time to assess the clinical and neuroradiological progression of cerebral amyloid angiopathy.
Follow-up visits as scheduled for up to 24 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Benedetta Storti, Giulia Marinoni, Benedetta Cefaloni...
https://pubmed.ncbi.nlm.nih.gov/40932118/Benedetta Storti, Antonella Capozza, Giulia Marinoni...
https://pubmed.ncbi.nlm.nih.gov/42085649/Benedetta Storti, Mario Stanziano, Giulia Marinoni...
https://pubmed.ncbi.nlm.nih.gov/40626372/Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead Sponsor